This week on LSCDS #ScienceNews and #Innovation:
After terminating their clinical trials for aducanumab in March 2019, Biogen has announced it will be seeking FDA approval for the controversial Alzheimer’s drug. This sudden turnaround helps revive the amyloid hypothesis of Alzheimer’s disease, which lost credibility after the initial cancellation of aducanumab trials.
And as we enter flu season, researchers believe they are getting closer to a universal flu vaccine following the discovery of a specific neuraminidase blocking antibody.
Finally, the NIH with the Bill and Melinda Gates Foundation has committed 200M in new funding for gene therapy research, targeting sickle cell disease and HIV.